Alkem Labs Launches Affordable Semaglutide Injection in India
Alkem Laboratories has announced the launch of its semaglutide injection in India, offering a significantly more affordable treatment option for patients with type 2 diabetes and obesity. The company stated that the weekly therapy cost will start at just ₹450, making it one of the most competitively priced semaglutide offerings in the market.
Semaglutide, a GLP-1 receptor agonist, is widely used for improving blood sugar control and supporting weight management. Its growing popularity globally has been driven by strong clinical outcomes, but high costs have limited accessibility for many patients in India. Alkem’s latest launch aims to bridge this gap by providing a cost-effective alternative without compromising on quality.
The introduction of a low-cost weekly injection is expected to intensify competition among pharmaceutical companies and accelerate the adoption of advanced diabetes therapies in the country. With India witnessing a rapid rise in diabetes cases, affordable and innovative treatment options are becoming increasingly important.
Alkem Labs’ move reinforces its commitment to expanding its portfolio in chronic therapies and improving access to essential healthcare solutions across India.